> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# LivaNova Sleep Apnea Device Meets Endpoints
- URL: https://www.fdaweb.com/livanova-sleep-apnea-device-meets-endpoints/
- Published: 2024-11-13T12:00:00.000Z
- Updated: 2026-09-14T14:46:53.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5158175

LivaNova says its aura6000 system, indicated to treat obstructive sleep apnea using targeted hypoglossal nerve stimulation, met the primary safety and efficacy endpoints in the OSPREY trial. A company [statement](https://investor.livanova.com/news-releases/news-release-details/livanova-announces-osprey-clinical-study-meets-primary-safety?ref=fdaweb.com) describes the aura6000 as an implantable hypoglossal neurostimulator intended to treat adults with moderate to severe obstructive sleep apnea.

Once the six-month results analysis is completed, the statement says, the OSPREY clinical data will be submitted to FDA as part of the premarket submission for the aura6000.